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Bioinformatics uses statistics and computer science to
process heterogeneous biological data, which provides
opportunities for understanding disease genetics, bio-
logical processes and identifying therapeutic targets [1].
During the last decades, drug discoveries have tuned
into the combination of experimental approaches and
modern science of computational. Various tools and
techniques have been used for target identification, en-
richment analysis and network algorithm. To date, sev-
eral in silico bioinformatic methods have been developed
and applied [2,3]. Drug targets have been predicted by
using chemical two-dimensional structural similarity ap-
proach and Bipartite graph learning method [4], in
which inverse-docking approach plays an important role
in target identification [5,6].
Inverse docking is a novel technology that can dock a
compound with known biological activity into the binding
sites of all 3D structures in given protein database [7]. The
procedure of docking involves multiple conformer shape-
matching alignment of drug molecule to a cavity followed
by molecular-mechanics torsion optimization and energy
minimization on both the molecule and the protein resi-
dues at the binding region [8]. And the screening is con-
ducted by the evaluation of molecular mechanics energy,
and the potential protein ‘hits’ can be selected by further
analysis of binding competitiveness against other ligands
that bind to the same receptor site [9]. Further, the most
commonly used drug target database is potential drug tar-
get database (PDTD, http://www.dddc.ac.cn/pdtd/), which
it contains 1207 entries covering 841 known and potential
drug targets with structures from the Protein Data Bank
(PDB) [10]. There are also a number of academic or com-
mercial available pathway databases and network building
tools, such as MetaCore™ and Integrity SM [11,12]. Meta-
Core™ is one of the most suitable tools for functional min-
ing of large, inherently noisy experimental datasets, and
the network visualization of drug-target, target disease
and disease-gene associations can provide useful informa-
tion for studies of therapeutic indications and adverse ef-
fects of drugs [13,14].
Traditional Chinese medicines (TCMs) have been used
to treat many diseases for thousands of years. Dioscin, a
natural steroidal saponin, exists in many Chinese medical
herbs including Dioscorea nipponica Makino, Dioscorea
zingiberensis C. H. Wright and Dioscorea futschauensis
Uline. Pharmarcological studies have showed that dioscin
has anti-tumor, anti-hyperlipidemic, anti-fungal and anti-
virus activities [15-18]. And our previous studies showed
that dioscin has significant hepatoprotective effects on
carbon tetrachloride (CCl4) and acetaminophen induced
liver damage in mice [19-21]. In the future, more and
more researches of dioscin will be investigated because of
its important medical value. How will the studies bedefined in terms of targets priorities, biological activities,
signal pathways and regulating networks affected by the
compound? In routine works, the experiments with a lot
of blindness should be carried out step-by-step [22,23],
and they will last a long time with time consuming and la-
borious. Thus, a prediction of the drug targets, biological
activity, signal pathways and regulatory pathways is neces-
sary, and it will provide complementary and supporting
evidence for the next experiments studies.
In the present paper, the drug-targets were predicted
based on inverse docking, and enrichment analysis and
network assays of dioscin were carried out by GeneGo’s
MetaCore™ techniques. Some possible targets, biological
activities, signal pathways and regulating networks of dios-
cin were predicted in advance, which should provide use-
ful information for further investigation.
Methods
System
In the present paper, 2D chemical structure of dioscin was
sketched using MarvinSketch (http://www.chemaxon.
com), and three-dimension (3D) structure of dioscin was
constructed using ISIS/Draw (ISIS/Draw, MDL Informa-
tion Systems, Inc., San Leandro, CA, USA). Then, the
identification and validation of all potential targets of dios-
cin were carried out by MDock software. The MDock is
automated molecular docking software for simultaneously
docking dioscin with known/available three-dimension
crystal structure against drug targets from PDTD with
multiple protein structure/conformations downloaded
from RCSB Protein Data Bank (PDB) by using the ensem-
ble docking algorithm [24]. After that, MetaCore platform
was used to analysis the biological activities, signal path-
ways and regulating networks, which is a suite of software
oriented toward understanding the function of gene sets
discovered by expression analysis (Table 1) and based on a
proprietary manually curated database of protein-protein,
and protein-DNA interactions, metabolic and signaling
pathways. The analysis process of the prediction of drug
targets, biological activities, signal pathway and regulating
networks is shown in Figure 1.
Target protein screening
In the procedure of screening targets, the chemical struc-
ture of dioscin was sketched to three-dimension structure
by ISIS/Draw for identifying potential biological targets.
Then, the structure file was uploaded to the MDock soft-
ware, the binding site analysis was applied with PDTD. In
the procedure, the binding site analysis enable to identify
and characterize a protein’s binding site, then use those
characteristics to look for similar features in other pro-
teins. The active site and binding energy (kcal/mol) of
them were defined and calculated, when the potential
drug target proteins were founded. And the threshold
Figure 1 The analysis process of the prediction of drug targets, biolo
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The corresponding gene of screened target proteins were
uploaded to MetaCore platform, and the functional ana-
lyses of related data were worked out by ontology enrich-
ment analysis based gene ontology. Here, the category of
GeneGo biological processes were chosen, which includes
some prebuilt molecular interaction networks, including
protein-protein and protein-compounds metabolites,
protein-nucleic acid interactions between all the networks.
At first, the data should be activated. When analyzing
data, make sure that the threshold is set appropriately.
In the analysis settings, the fold change threshold was
set at 0.001, and the p-value threshold was 0.05. Namely,
any genes with fold change values less than 0.001 were fil-
tered out. Meanwhile, p-value threshold filters out genes
with a p-value of more than 0.05. Other parameters also
were set before analysis, such as signals was set as both,
sorting method was set as statistically significant.
The enrichment analysis consists of matching gene
IDs of possible targets for the “common”, “similar” and
“unique” sets with gene IDs in functional ontologies in
MetaCore. The probability of a random intersectiongical activities, signal pathway and regulating networks.
Table 2 The target proteins of dioscin from human, rat and mouse searched in PDTD
No PDB Uniprot_id Gene symbol Protein name Gene id Energy
Human
1 2old - - Immune system - −64.3
2 1iyh PTGD2_HUMAN PTGDS2 Glutathione-requiring prostaglandin D synthase 27306 −65.2
3 1udu PDE5A_HUMAN PDE5A cGMP-specific 3′,5′-cyclic phosphodiesterase 8654 −58
4 2ax4 PAPS2_HUMAN PAPSS2 Bifunctional 3′-phosphoadenosine
5′-phosphosulfate synthetase 2
9060 −73.8
5 1ivo EGFR_HUMAN EGFR Epidermal growth factor receptor [Precursor] 1956 −67.4
6 2a73 CO3_HUMAN C3 Complement C3 [Precursor] 718 −67.6
7 1ivo EGF_HUMAN EGF Pro-epidermal growth factor [Precursor] 1950 −67.4
8 1xbt KITH_HUMAN TK1 Thymidine kinase, cytosolic 7083 −71
9 1w4r KITH_HUMAN TK1 Thymidine kinase, cytosolic 7083 −70.2
10 1l5q PYGL_HUMAN PYGL Glycogen phosphorylase, liver form 5836 −68.8
11 1pl2 GSTA1_HUMAN GSTA1 Glutathione S-transferase A1 2938 −65.1
12 1m5o SNRPA_HUMAN SNRPA U1 small nuclear ribonucleoprotein A 6626 −74
13 1tl8 TOP1_HUMAN TOP1 DNA topoisomerase 1 7150 −55.2
14 1rr8 TOP1_HUMAN TOP1 DNA topoisomerase 1 7150 −62.1
15 1nd6 PPAP_HUMAN ACPP Prostatic acid phosphatase [Precursor] 55 −57.7
16 2c5n CCNA2_HUMAN CCNA2 Cyclin-A2 890 −72.2
17 2c6t CCNA2_HUMAN CCNA2 Cyclin-A2 890 −67.4
18 2c5x CCNA2_HUMAN CCNA2 Cyclin-A2 890 −73.8
19 1yah EST1_HUMAN CES1 Liver carboxylesterase 1 [Precursor] 1066 −68.3
20 2c5n CDK2_HUMAN CDK2 Cell division protein kinase 2 1017 −72.2
21 2c6t CDK2_HUMAN CDK2 Cell division protein kinase 2 1017 −67.4
22 2c5x CDK2_HUMAN CDK2 Cell division protein kinase 2 1017 −73.8
23 1sk6 CYAA_BACAN cya Calmodulin-sensitive adenylate cyclase [Precursor] 2820138 −63.3
24 1sk6 CYAA_BACAN cya Calmodulin-sensitive adenylate cyclase [Precursor] 3361726 −63.3
25 2a4z PK3CG_HUMAN PIK3CG Phosphatidylinositol-4,5-bisphosphate 3-kinase
catalytic subunit gamma isoform
5294 −61.2
26 1sa4 FNTA_HUMAN FNTA Protein farnesyltransferase/geranylgeranyltransferase
type-1 subunit alpha
2339 −63.5
27 1sa4 FNTB_HUMAN FNTB Protein farnesyltransferase subunit beta 2342 −63.5
28 1h2v NCBP2_HUMAN NCBP2 Nuclear cap-binding protein subunit 2 22916 −61.2
29 2uym KIF11_HUMAN KIF11 Kinesin-like protein KIF11 3832 −58.8
30 1ko6 NUP98_HUMAN NUP98 Nuclear pore complex protein Nup98-Nup96 [Precursor] 4928 −74.2
31 2i6a ADK_HUMAN ADK Adenosine kinase 132 −66.6
32 2fdp BACE1_HUMAN BACE1 Beta-secretase 1 [Precursor] 23621 −70.2
33 2ic5 RAC3_HUMAN RAC3 Ras-related C3 botulinum toxin substrate 3 [Precursor] 5881 −75.3
34 1sk6 CALM_HUMAN CALM1 Calmodulin 801 −63.3
35 1sk6 CALM_HUMAN CALM1 Calmodulin 808 −63.3
36 1sk6 CALM_HUMAN CALM1 Calmodulin 805 −63.3
37 1 m63 PPIA_HUMAN PPIA Peptidyl-prolyl cis-trans isomerase A 5478 −81.3
38 1 m63 PPIA_HUMAN PPIA Peptidyl-prolyl cis-trans isomerase A 653214 −81.3
39 1 m63 PPIA_HUMAN PPIA Peptidyl-prolyl cis-trans isomerase A 654188 −81.3
40 1 m63 CANB1_HUMAN PPP3R1 Calcineurin subunit B type 1 5534 −81.3
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Table 2 The target proteins of dioscin from human, rat and mouse searched in PDTD (Continued)
41 1y4v HBB_HUMAN HBB Hemoglobin subunit beta 3043 −79.9
42 1y4g HBB_HUMAN HBB Hemoglobin subunit beta 3043 −62.1
43 1y45 HBB_HUMAN HBB Hemoglobin subunit beta 3043 −57.1
44 1y85 HBB_HUMAN HBB Hemoglobin subunit beta 3043 −55.6
45 1rq3 HBB_HUMAN HBB Hemoglobin subunit beta 3043 −63
46 1y46 HBB_HUMAN HBB Hemoglobin subunit beta 3043 −59.4
47 1y7g HBB_HUMAN HBB Hemoglobin subunit beta 3043 −71.9
48 1y4q HBB_HUMAN HBB Hemoglobin subunit beta 3043 −73.6
49 1y4v HBA_HUMAN HBA1 Hemoglobin subunit alpha 3039 −79.9
50 1y4v HBA_HUMAN HBA1 Hemoglobin subunit alpha 3040 −79.9
51 1y4g HBA_HUMAN HBA1 Hemoglobin subunit alpha 3040 −62.1
52 1y4g HBA_HUMAN HBA1 Hemoglobin subunit alpha 3039 −62.1
53 1y45 HBA_HUMAN HBA1 Hemoglobin subunit alpha 3040 −57.1
54 1y45 HBA_HUMAN HBA1 Hemoglobin subunit alpha 3039 −57.1
55 1y85 HBA_HUMAN HBA1 Hemoglobin subunit alpha 3040 −55.6
56 1y85 HBA_HUMAN HBA1 Hemoglobin subunit alpha 3039 −55.6
57 1rq3 HBA_HUMAN HBA1 Hemoglobin subunit alpha 3040 −63
58 1rq3 HBA_HUMAN HBA1 Hemoglobin subunit alpha 3039 −63
59 1y46 HBA_HUMAN HBA1 Hemoglobin subunit alpha 3040 −59.4
60 1y46 HBA_HUMAN HBA1 Hemoglobin subunit alpha 3039 −59.4
61 1y7g HBA_HUMAN HBA1 Hemoglobin subunit alpha 3040 −71.9
62 1y7g HBA_HUMAN HBA1 Hemoglobin subunit alpha 3039 −71.9
63 1y4q HBA_HUMAN HBA1 Hemoglobin subunit alpha 3040 −73.6
64 1y4q HBA_HUMAN HBA1 Hemoglobin subunit alpha 3039 −73.6
65 1fro LGUL_HUMAN GLO1 Lactoylglutathione lyase 2739 −67.4
66 1 m63 PP2BA_HUMAN PPP3CA Serine/threonine-protein phosphatase 2B
catalytic subunit alpha isoform
5530 −81.3
67 1h2v NCBP1_HUMAN NCBP1 Nuclear cap-binding protein subunit 1 4686 −61.2
68 2gk6 RENT1_HUMAN UPF1 Regulator of nonsense transcripts 1 5976 −72.9
69 2ovp FBXW7_HUMAN FBXW7 F-box/WD repeat-containing protein 7 55294 −63.5
70 2pfo DPOLL_HUMAN POLL DNA polymerase lambda 27343 −60.7
71 2 h16 ARL5A_HUMAN ARL5A ADP-ribosylation factor-like protein 5A 26225 −66.6
Rat
1 1cte CATB_RAT Ctsb Cathepsin B [Precursor] - −65.8
2 1ewk GRM1_RAT Grm1 Metabotropic glutamate receptor 1 [Precursor] 24414 −68.6
3 1zzu NOS1_RAT Nos1 Nitric oxide synthase, brain 24598 −74.3
4 1rs6 NOS1_RAT Nos1 Nitric oxide synthase, brain 24598 −76.2
5 1kzo FNTB_RAT Fntb Protein farnesyltransferase subunit beta 64511 −67.4
6 2bed FNTB_RAT Fntb Protein farnesyltransferase subunit beta 64511 −71.5




1 2ihm DPOLM_MOUSE Polm DNA polymerase mu 54125 −59.2
2 1f3a GSTA1_MOUSE Gsta1 Glutathione S-transferase A1 14857 −63
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Table 2 The target proteins of dioscin from human, rat and mouse searched in PDTD (Continued)
3 2oi9 HA1L_MOUSE H2-L H-2 class I histocompatibility antigen,
L-D alpha chain [Precursor]
- −62.1
4 1iea HA21_MOUSE H2-Ea H-2 class II histocompatibility antigen,
E-D alpha chain [Precursor]
- −66.5
5 1fng HA22_MOUSE - H-2 class II histocompatibility antigen,
E-K alpha chain [Precursor]
- −66.1
6 1qom NOS2_MOUSE Nos2 Nitric oxide synthase, inducible 18126 −66.2
7 2gb4 TPMT_MOUSE Tpmt Thiopurine S-methyltransferase 22017 −57.5
8 2oi9 TVA1_MOUSE - T-cell receptor alpha chain V region
PHDS58 [Precursor]
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ogy entities is estimated in p-value of hypergeometric
intersection. The lower p-value means higher relevance of
the entity to the dataset, which shows in higher rating for
the entity. The ontologies include GeneGo Pathway Maps,
GeneGo process Networks, Go Processes and GeneGo
Diseases (by Biomarkers). The degree of relevance to dif-
ferent categories for the uploaded datasets is defined by
p-values, and so the lower p-value gets higher priority.
The distributions are calculated and showed as histograms
of 10 most significant results (ranked by the-log (p-value)).
Most relevant networks analysis
The gene of the uploaded files is used as the input list
for gene statistics analysis, the correlation between gene
and network objects were obtained, and the intensity
corresponds to the expression values were provided.
Then, the obtained results were used for network statis-
tics based networks built from active experiments, the
relevant network objects of each network were listed, in-
cluding the divergence hubs convergence hubs, edges in
and edges out. The generation of biological networks
uses Analyze Networks (AN) algorithm with default set-
tings. This is a variant of the shortest paths algorithm
with main parameters of relative enrichment with the
uploaded data, and relative saturation of networks with
canonical pathways. These networks are built on the fly
and unique for the uploaded data. In this workflow the
networks are prioritized based on the number of frag-
ments of canonical pathways on the network.
Results and discussion
Target proteins
Inverse docking was used to identify new potential bio-
logical targets, or to identify target for components among
a family of related receptors. In the present paper, 71 po-
tential targets of dioscin identified from humans’ proteins,
7 from rats and 8 from mice were screened by MDock
software. These target proteins belong to enzymes, G-
protein-coupled, receptors, ion channels, and nuclear re-
ceptors, which are listed in Table 2.Enrichment analysis
GeneGo pathway Maps
It is generally recognized that the pathway-based ana-
lysis can provide much significant information. Canon-
ical pathway maps represent a set of about 650 signaling
and metabolic maps covering human biology (signaling
and metabolism) in a comprehensive way. The profile of
network objects (Table 3) was uploaded to search canon-
ical pathway maps. All maps are drawn from scratch by
GeneGo annotators and manually curated & edited.
From the distributions shown in Figure 2, the most sig-
nificantly multistep pathways from literature consensus
were enriched in the data set. Experimental data is visu-
alized on the maps as yellow (for down-regulation) histo-
grams. The height of the histogram corresponds to the
relative expression value for a particular gene/protein.
Top scored pathway maps were sorted by statistically sig-
nificant Maps (Figure 3). The top scored pathway maps
were immune response alternative complement pathway,
G-protein signaling_RhoB regulation pathway and immune
response antiviral actions of interferons, respectively. Ex-
perimental data from all files is linked to and visualized on
the maps as thermometer-like figures. Up-ward thermome-
ters have red color and indicate up-regulated signals and
down-ward (blue) ones indicate down-regulated expression
levels of the genes.
Complement system can protect the host from micro-
organisms [25], and the alternative pathway can be dir-
ectly activated by invading microorganisms. C3/C5
convertases which are complex enzymes transiently as-
sembled on the surface of biological organisms upon ac-
tivation of the complement system [26]. The generation
of active C3/C5 convertases help opsonize, kill, and clear
bacteria, parasites and pathogens by eliciting cellular
functions including phagocytosis and inflammation [27].
In the map of human, it is initiated by the spontaneous
hydrolysis of C3 which is a major effector of humoral
branch of the complement system. The down-regulation
of C3 treated by dioscin contributes to the down-
regulation of C3a and C3b, and then they induce the
down-regulation of C5 convertase. For the linkage effect,
Table 3 The Network objects and its functions
No Species Gene Name Network Objects Protein Function
1 Homo sapiens ACPP PPAP Protein phosphatase
2 Homo sapiens ADK Adenosine kinase Generic kinase
3 Homo sapiens ARL5A ARL5 RAS superfamily
4 Homo sapiens BACE1 BACE1 Generic protease
5 Homo sapiens C3 C3 Generic binding protein
C3a Generic binding protein
C3b Generic binding protein
C3c Generic binding protein
C3dg Generic binding protein
C5 convertase (C2aC4bC3b) Generic protease
C5 convertase (C3bBb) Generic protease
iC3b Generic binding protein
6 Homo sapiens CALM1 Calmodulin Generic binding protein
7 Homo sapiens CALM2 Calmodulin Generic binding protein
8 Homo sapiens CALM3 Calmodulin Generic binding protein
9 Homo sapiens CCNA2 Cyclin A Generic binding protein
Cyclin A2 Generic binding protein
10 Homo sapiens CDK2 CDK2 Protein kinase
11 Homo sapiens CES1 CES1 Generic enzyme
12 Homo sapiens EGF EGF Receptor ligand
13 Homo sapiens EGFR EGFR Receptor with enzyme activity
14 Homo sapiens FBXW7 Cul1/Rbx1 E3 ligase Generic enzyme
FBXW7 Generic binding protein
Skp2/TrCP/FBXW Generic binding protein
15 Homo sapiens FNTA FTase Generic enzyme
FTase-alpha Generic enzyme
GGTase-I Generic enzyme
16 Homo sapiens FNTB FTase Generic enzyme
FTase-beta Generic enzyme
17 Homo sapiens GLO1 Glyoxalase I Generic enzyme
18 Homo sapiens GSTA1 GSTA1 Generic enzyme
19 Homo sapiens HBA1 Adult hemoglobin Generic protein
Alpha1-globin Transporter
HP/HB complex Generic protein
20 Homo sapiens HBA2 Adult hemoglobin Generic protein
Alpha1-globin Transporter
HP/HB complex Generic protein
21 Homo sapiens HBB Adult hemoglobin Generic protein
HBB Transporter
HP/HB complex Generic protein
22 Homo sapiens HPGDS PGDS Generic enzyme
23 Homo sapiens KIF11 KNSL1 Generic binding protein
24 Homo sapiens NCBP1 CBP80 Generic binding protein
25 Homo sapiens NCBP2 CBP20 Generic binding protein
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Table 3 The Network objects and its functions (Continued)
26 Homo sapiens NUP98 NUP98 Generic channel
NUP98/HHEX fusion protein Transcription factor
NUP98/HOXA9 fusion protein Transcription factor
Nuclear pore complex proteins Generic channel
27 Homo sapiens PAPSS2 PAPSS2 Generic kinase
28 Homo sapiens PDE5A PDE Generic protein
PDE5A Generic enzyme
29 Homo sapiens PIK3CG PI3K cat class IB (p110-gamma) Lipid kinase
30 Homo sapiens POLL DNA polymerase lambda Generic enzyme
31 Homo sapiens PPIA Cyclophilin A Generic enzyme
32 Homo sapiens PPP3CA Calcineurin A (alpha) Protein phosphatase
Calcineurin A (catalytic) Protein phosphatase
33 Homo sapiens PPP3R1 Calcineurin B (regulatory) Generic binding protein
Calcineurin B1 Generic binding protein
34 Homo sapiens PYGL Glycogen phosphorylase Generic enzyme
PYGL Generic enzyme
35 Homo sapiens RAC3 Rac3 RAS superfamily
36 Homo sapiens SNRPA SNRPA Generic binding protein
37 Homo sapiens TK1 TK1 Generic kinase
38 Homo sapiens TOP1 TOP1 Generic enzyme
39 Homo sapiens UPF1 RENT1 Generic binding protein
1 Rattus norvegicus Ctsb Cathepsin B Generic protease
2 Rattus norvegicus Fnta FTase Generic enzyme
FTase-alpha Generic enzyme
GGTase-I Generic enzyme
3 Rattus norvegicus Fntb FTase Generic enzyme
FTase-beta Generic enzyme




5 Rattus norvegicus Nos1 nNOS Generic enzyme
1 Mus musculus Gsta1 Gsta1 (mouse) Generic enzyme
2 Mus musculus H2-D1 HLA-B Generic receptor
MHC class I Generic receptor
3 Mus musculus H2-Ea HLA-DRA1 Generic receptor
MHC class II Generic receptor
MHC class II alpha chain Generic receptor
4 Mus musculus H2-Ea HLA-DRA1 Generic receptor
MHC class II Generic receptor
MHC class II alpha chain Generic receptor
5 Mus musculus H2-L H-2 L(d) Generic receptor
HLA-C Generic receptor
MHC class I Generic receptor
6 Mus musculus Nos2 iNOS Generic enzyme
7 Mus musculus OTTMUSG00000015050 Trav9d-4 Generic receptor
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Table 3 The Network objects and its functions (Continued)
8 Mus musculus Polm DNA polymerase mu Generic enzyme
9 Mus musculus Tpmt Thiopurine S-methyltransferase Generic enzyme
10 Mus musculus Uap1 UAP1 Generic enzyme
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fer affection, including CR1, C3aR, alpha-M/beta-2 in-
tegrin, alpha-X/beta-2 intetrin and CD21.
In the map of RhoB regulation pathway, RhoB is a
member of small GTPases family and can control mul-
tiple cellular processes, including actin and microtubule
dynamics, gene expression, cell cycle, cell polarity and
membrane transport. Their abilities are bound to nu-
merous downstream effectors which lead to diverseFigure 2 GeneGo Diseases (by Biomarkers) of human, rat and
mouse. Sorting is done for the “Statistically significant Diseases” set.parallel downstream signaling pathways [28]. There are
several classes of regulatory proteins affect the activation
of RhoB. Among them, GGTase-I (Geranylgeranyltrans-
ferase type I) and FTase (Farnesyltransferase CAAX box)
promote post-translational modification of RhoB (Ras
homolog gene family, member A) protein by geranyl-
geranylation and farnesylation, which are essential for
the biological activity of RhoB. In the prediction, down-
regulated expression of RhoB gene was induced by down-
regulations of GGTase-I and FTase treated with dioscin.
In the map of immune response antiviral actions of in-
terferons, iNOS (inducible NO synthase) was the network
object. iNOS generates copious amounts of NO pre-
sumably to help kill or inhibit the growth of invading
microorganisms or neoplastic tissue [29]. Over-expression
of iNOS, a common phenomenon during chronic inflam-
matory conditions, generates sustainable amounts of NO.
Its reactive intermediates are mutagenic, causing DNA
damage or impairment of DNA repair. Recent studies also
implicated NO as a key signaling molecule which can
regulate the processes of tumorigenesis. Increased expres-
sion of iNOS is involved in tumors of the colon, lung, oro-
pharynx, reproductive organs, breast, and CNS (Central
Nervous System) [30]. Thus, the map indicated that dios-
cin can down regulate the expression level of iNOS gene.
Namely, it may be a selective inhibitor of iNOS for che-
moprevention of cancer.GeneGo process networks and Go processes
In the GeneGo process networks analysis, sorting is
done for the ‘Statistically significant Networks’ set. There
are about 110 cellular and molecular processes whose
content is defined and annotated by GeneGo. According
to the experimental data (Table 3), ten processes net-
works with lower p-value were obtain (Table 4). In Go
processes, the original Gene Ontology (GO) cellular pro-
cesses, represented at GeneGo were included. Since
most of GO processes have no gene/protein content, the
“empty terms” are excluded from p-value calculations,
and ten processes with lower p-values were obtain
(Table 4). The results are all consistent with GeneGo
pathway maps, they were associated with immune re-
sponse, inflammation and cell cycle signaling, the Go
processes include regulation of immune response, DNA
replication, RNA transport, protein amino acid famesyla-
tion, and regulation of cell killing etc. . GeneGo Diseases
(by Biomarkers).
Figure 3 GeneGo Pathway Maps. Sorting is done for the “Statistically significant Maps” set.
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(Table 3) to discover and validate biomarker. Using bio-
informatics approaches, numerous candidate biomarkers
associated with the development or prognosis of human
disease were reported. Disease folders represent over 500
human diseases with gene content annotated by GeneGo.
Disease folders are organized into a hierarchical tree.
In the paper, the enriched disease was detected by the
biomarkers. Using network objects known (Table 3) to beassociated with dioscin as set of interest, the frequency was
recomputed by summing object occurrences for disease.
Then, p-values were obtained, which assumes that the
probability of picking a network objects annotated with a
disease in the reference set. The results are shown in
Figure 4. Gene contents may be different greatly between
two complex diseases such as cancers and Mendelian dis-
eases. Also, coverages of different diseases in literature are
skewed. The two factors may affect p-value prioritization.
Table 4 Ten GeneGo process networks and Go processes with lower p-values
GeneGo process network
Network Objects Name p-value
Human 51 Development_Hemopoiesis, Erythropoietin pathway 0.000003178
Inflammation_Complement system 0.00002487
Cell cycle_G2-M 0.00004606
Signal transduction_WNT signaling 0.0001901
Signal Transduction_TGF-beta, GDF and Activin signaling 0.0007943
Cell cycle_G1-S 0.001089
Cell cycle_Meiosis 0.00169
Cell cycle_G1-S Growth factor regulation 0.00215
Muscle contraction_Nitric oxide signaling in the cardiovascular system 0.00228
Protein folding_Folding in normal condition 0.002583
Rat 7 Neurophysiological process_Transmission of nerve impulse 0.0005214
Signal Transduction_TGF-beta, GDF and Activin signaling 0.006777
Reproduction_GnRH signaling pathway 0.008233
Development_Neurogenesis: Synaptogenesis 0.009411
Cell adhesion_Synaptic contact 0.009819
Reproduction_Gonadotropins regulation 0.01165
Neurophysiological process_Taste signaling 0.02996
Cell cycle_G0-G1 0.05999
Neurophysiological process_Circadian rhythm 0.0641
Neurophysiological process_Long-term potentiation 0.06901
Mouse 11 Immune_Antigen presentation 0.0002078
Immune_Phagosome in antigen presentation 0.0004253
Immune_Innate immune response to RNA viral infection 0.001665
Inflammation_NK cell cytotoxicity 0.00532





Muscle contraction_Nitric oxide signaling in the cardiovascular system 0.08035
Go processes
Network Objects Name pValue
Human 51 DNA replication 9.331E-09
protein localization in nucleus 6.994E-08
mRNA transport 1.706E-07
protein amino acid farnesylation 1.928E-07
positive regulation of biological process 2.181E-07
establishment of RNA localization 2.994E-07




Rat 7 protein amino acid farnesylation 4.46E-10
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Table 4 Ten GeneGo process networks and Go processes with lower p-values (Continued)
protein farnesylation 8.918E-10
positive regulation of nitric-oxide synthase 2 biosynthetic process 1.56E-09
regulation of nitric-oxide synthase 2 biosynthetic process 2.496E-09
protein amino acid prenylation 9.799E-09
protein prenylation 1.274E-08
regulation of sensory perception of pain 1.455E-07
regulation of sensory perception 1.455E-07
synaptic transmission 3.092E-07
transmission of nerve impulse 6.724E-07
Mouse 11 antigen processing and presentation of exogenous peptide antigen 4.316E-11
antigen processing and presentation of exogenous antigen 9.457E-11
antigen processing and presentation of peptide antigen 2.176E-10
antigen processing and presentation 4.237E-09
regulation of immune response 1.693E-08
positive regulation of leukocyte mediated cytotoxicity 1.706E-08
positive regulation of cell killing 2.148E-08
positive regulation of immune system process 2.238E-08
regulation of leukocyte mediated cytotoxicity 4.251E-08
regulation of cell killing 5.109E-08
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tal autoimmune encephalomyelitis, experimental nervous
system autoimmune disease, hypertrophic cicatrix, cicatrix,
hemolytic-uremic syndrome, complex and mixed neo-
plasms, uremia, toxic hepatitis, drug-induced chronic
hepatitis, brain ischemia. For rat, dioscin may associate it-
self with temporal lobe epilepsy, partial epilepsies, amyo-
trophic lateral sclerosis, melanoma, motor neuron disease,
nevi and melanomas, spinal cord diseases, neuroendocrine
tumors, hamartoma and epilepsy. For mouse, dioscin may
associate itself with ankylosing spondylitis, ulcerative col-
itis, spondylitis, ankylosis, infectious bone diseases, colitis,
spondylarthropathies, spondylarthritis, autoimmune hepa-
titis, spinal diseases.
The most relevant networks
The network analysis can provide primary information
about physical connectivity and functional relationships
between proteins/genes. MetaCore database is suitability
for manually curated interactions database over 90% hu-
man proteins with known function [31]. MetaCore has
four “Analyze” network algorithms which are useful when
we have a large number of network objects. Among them,
analyze network creates a large network and breaks it up
into smaller sub-networks which are all ranked by p-value.
And analyze transcription regulation works in a similar
way. The other two “Analyze” network algorithms (tran-
scription factors and receptors) focus on the presence of
either start-nodes or end-nodes of a certain pathway. Inthe paper, the biological networks were created by Analyze
networks algorithm, and the related objects used for net-
work building are listed in Table 3.
As all objects on the networks are annotated, they can
be associated with one or more cellular functions includ-
ing DNA repair, cell cycle or apoptosis. The networks can
be scored and prioritized based on statistical “relevance”
in the function processes and maps. Each network is asso-
ciated with a g-score and p-value. The priority can be de-
fined as a proportion of the nodes with the data to the
total number of nodes on the networks measured with z-
score value. In general, a high positive g-score means it is
highly saturated with genes from the experiment data.
The g-score, p-values and z-score of networks are listed
in Table 5, and the top two networks of each species are
shown in Figure 5. Relative intensity corresponds to the
expression value. Unregulated genes are marked with red
circles, while down regulated genes with blue circles. The
‘checkerboard’ color indicates mixed expression for the
gene between files or between multiple tags for the same
gene.
The network (p=4.35e-39, g-score=93.09) resulting from
the experiment data is shown in Figure 5A. The c-Myc is
divergence hub, and the ESR1 (nuclear) is a convergence
hub in the network. The c-Myc protein is a key transcrip-
tional factor, and it is almost universally involved in cell
cycle progression, transformation and apoptosis through
targeting of downstream genes [32]. ESR1 (Arabidopsis
Enhancer of Shoot Regeneration 1) was identified as a
Figure 4 The top scored map (map with the lowest p-value) of human, rat and mouse based on the enrichment distribution sorted by
‘Statistically significant Maps’ set. Experimental data from all files is linked to and visualized on the maos as thermometer-like figures. Up-ward
thermometers have red color and indicate up-regulated signals and down-ward (blue) ones indicate down regulated expression levels of genes.
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Table 5 g-score, z-score and p-value of the most relevant networks
No Process Size Target p-value z-score g-score
Human
1 mRNA metabolic process (19.5%), 50 16 4.35e-39 80.59 93.09
RNA metabolic process (29.3%),
response to chemical stimulus (41.5%)
2 cell division (40.0%), 50 9 1.72e-21 55.79 55.79
mitosis (35.0%),
nuclear division(35.0%)
3 glycogen metabolic process (23.1%), 50 9 2.39e-21 54.90 54.90
cellular glucan metabolic process (23.1%),
glucan metabolic process (23.1%)
4 intracellular signaling cascade (51.3%), 50 11 2.32e-22 50.84 52.09
signal transduction (71.8%),
biological regulation (97.4%)
5 DNA metabolic process (40.5%), 50 9 1.15e-19 45.25 51.50
cellular response to DNA damage stimulus (31.0%),
response to DNA damage stimulus (31.0%)
Rat
1 peptidyl-cysteine S-nitrosylation (100.0%), 7 1 2.54e-04 62.68 62.68
drug catabolic process (100.0%),
exogenous drug catabolic process (100.0%)
2 regulation of metal ion transport (26.5%), 50 3 1.78e-08 39.59 39.59
regulation of ion transport (26.5%),
negative regulation of potassium ion transport (14.7%)
3 No processes found 4 0 1.00e + 00 0.00 0.00
Mouse
1 N-acetylglucosamine biosynthetic process (100.0%), 3 1 1.82e-04 74.17 74.17
UDP-N-acetylglucosamine biosynthetic process (100.0%),
glucosamine biosynthetic process (100.0%)
2 positive regulation of immune system process (44.8%), 50 5 1.42e-14 64.51 65.76
regulation of immune system process (51.7%),
regulation of response to stimulus (51.7%)
3 positive regulation of Schwann cell differentiation (50.0%), 16 1 5.45e-04 42.81 42.81
regulation of Schwann cell differentiation (50.0%),
response to cobalamin (50.0%)
4 response to other organism (100.0%), 5 1 9.08e-04 33.15 33.15
response to biotic stimulus (100.0%),
5 transepithelial chloride transport (33.3%), 9 1 1.09e-03 30.26 30.26
transepithelial transport (33.3%),
somatic hypermutation of immunoglobulin genes (33.3%)
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ciency when over-expressed [33]. The network includes
16 possible targets including ARL5, TOP1, HBB, KNSL1,
CBP80, CBP20, Calcineurin B, RENT1, SNRPA, CSTA1,
CES1, C3, EGFR, EGF, Alphal-globin and PDESA. EGF isa metastatic inducer of tumor cells, which activates epi-
dermal growth factor receptor (EGFR)-induced signal
pathway to induce cancer metastasis [34]. CES1 is the
most versatile human carboxylesterase, and it plays critical
roles in drug metabolism and lipid mobilization. Excessive
Figure 5 The top two networks scored by MetaCore (AN network) of human (A and B), rat (C and D) and mouse (E and F). A: mRNA
metabolic process, RNA metabolic process and response to chemical stimulus of human; B: cell division, mitosis and nuclear division; C: peptidyl-
cysteine S-nitrosylation, drug catabolic process and exogenous drug catabolic process; D: regulation of metal ion transport, ion transport and
negative regulation of potassium ion transport; E: N-acetylglucosamine biosynthetic, UDP-N-acetylglucosamine biosynthetic and glucosamine
biosynthetic process; F: positive regulation of immune system, regulation of immune system and response to stimulus. Thick cyan lines indicate
the fragments of canonical pathways. Upregulated genes are marked with red circles; downregulated with blue circles. The ‘checkerboard’ color
indicates mixed expression for the gene between files or between multiple tags for the same gene.
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anti-oxidants protective effect on human health [35]. The
cap-binding protein heterodimer CBP80-CBP20 initially
undergo a pioneer round of translation of newly synthe-
sixed messenger ribonucleoproteins (mRNPs) [36]. C3 is a
main complement in complement pathway [37]. TOP1
unwinds DNA by making transient single strand breaks
that relieves the tosion of supercoiled DNA.
The network (p=41.72e−21, g-score=55.79) is shown in
Figure 5B, which contains 9 of drug targets, including
Cyclin A, Cyclin A2, HBB, C3a, TOP1, KNSL1, NUP98,
TK1 and FBSW7. The divergence hub of the network was
c-Jun, and the convergence hubs were c-Jun, APC/Hcdh1
complex and dTMP cytoplasm. The c-Jun N-terminal kin-
ase (JNK) signaling pathway plays a critical role in inflam-
mation _ complement system [38]. JNK can be activated
by exposure of cells to cytokines or environmental stress,
indicating that this signaling pathway may contribute to
inflammatory responses [39]. And genetic and biochem-
ical studies demonstrate that this signaling pathway also
regulates cellular proliferation, apoptosis and tissue mor-
phogenesis [40].
The networks of rat are shown in Figure 5C and D, and
the networks of mouse are shown in Figure 5E and F.
From the networks, well connected clusters of root nodes
were found, and more flexibility in the connection were
presented. In Figure 5C, mitomycin C can treat a variety
of malignancies, such as head and neck cancers and super-
ficial transitional cell carcinoma of the bladder [41]. The
nNOS and mitomycin C is involved in a signal pathway,
nNOS is down regulated by dioscin while mitomycin C is
up-regulation. Thus, dioscin could be used to anti-cancer
through that pathway. In Figure 5E, N-acetylglucosamine-
1-phosphate catalyzes the formation of UDP-GlcNAC,
which is an essential precursor of petidoglycan and the
rhamnose-GlcNAc linker region of mycobacterial cell wall
[42]. Thus, dioscin may be a potential anti-infections drug
through down-regulation of UAP1.
All those results indicated that dioscin may exert bio-
logical effects through multi-channel. Such as, dioscin is
a TOP1 inhibitor, inhibits relegation and stabilizes the
DNA-TOP1 complex in the cleaved DNA form, ultim-
ately leading to breaks of DNA chains and cell death.
Thus, the dioscin could used to treat cancer though the
cell cycle–transition and termination of DNA replication
pathway. And it could inhibit cancer metastasis through
EGFR-induced signal pathway. In addition, it could be
used to treat inflammation though JNK signaling path-
way. However, the dioscin may induce some side effect
by down-regulation of complement system.
Conclusions
In the paper, we presented an application of in-silico in-
verse docking technique coupled with bioinformaticsapproach to predict the possible targets, biological activ-
ities, signal pathways and regulating networks of dioscin.
Those studies provide valuable information for future
in vitro and in vivo works to validate the previous in
silico findings.
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